Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
NCT00958633 · University of British Columbia · PHASE3 · terminated · last registry update 2025-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment was stopped before the planned sample size was reached owing to the Covid-19 pandemic and expiration of funding.” | – | Registry record, University of British Columbia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-12Also stopped (terminated): University of Wisconsin, Madison, Psilocybin (NCT05322954)
- 2026-05-04Also stopped (withdrawn): University of Southern California, Trazodone + Quetiapine (NCT05085808)
- 2026-04-23Results posted on the registry: University of Chicago, Caplyta + Placebo (NCT05356013)
- 2026-04-16Results posted on the registry: University of California, Irvine, Nortriptyline + Topiramate + Verapamil + Paroxetine (NCT04404439)
- 2026-04-14Results posted on the registry: University of Florida, Fluoxetine + Calcium (NCT04850222)
- 2026-04-09Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05697835)
- 2026-04-09Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05575128)
- 2026-03-31Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05685511)
- 2026-03-19Results posted on the registry: Duke University, 5% lidocaine/5 mg/ml 0.02% estradiol compound cream + Nortriptyline (NCT03844412)
- 2026-01-29Results posted on the registry: Friends Research Institute, Inc., a drug against SLC6A4 (NCT03884946)
- 2026-01-23Results posted on the registry: Hanoi Medical University, a drug against SLC6A4 (NCT04706624)
- 2026-01-21Also stopped (terminated): Shanghai Mental Health Center, conventional medical treatment (TAU) (NCT05528224)
- 2026-01-16Results posted on the registry: Ryan M. Carnahan, a drug against SLC6A4 (NCT04449055)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-12-10Results posted on the registry: Case Comprehensive Cancer Center, Escitalopram (NCT05289830)
- 2025-12-10Also stopped (terminated): Case Comprehensive Cancer Center, Escitalopram (NCT05289830)
- 2025-12-02Results posted on the registry: University of California, San Francisco, Fluoxetine (NCT03466346)
- 2025-11-28Phase 3 first posted: Zhejiang Huahai Pharmaceutical Co., Ltd., Levomilnacipran Hydrochloride Extended-Release Capsules + Duloxetine Hydrochloride Enteric Capsules (NCT07253207)
- 2025-11-12Results posted on the registry: Intra-Cellular Therapies, Inc., Lumateperone 42 mg + Lumateperone 28 mg (NCT04779177)
- 2025-11-03Results posted on the registry: Intra-Cellular Therapies, Inc., Lumateperone (NCT05061719)
- 2025-11-03Results posted on the registry: Intra-Cellular Therapies, Inc., ITI-007 (Lumateperone) + Placebo (NCT02600494)
- 2025-10-27Results posted on the registry: Glenn-Milo Santos, Naltrexone Hydrochloride + Placebo (NCT04791969)
- 2025-10-03Results posted on the registry: Intra-Cellular Therapies, Inc., ITI-007 + Placebo (NCT01499563)
- 2025-10-02Results posted on the registry: Intra-Cellular Therapies, Inc., ITI-007 + Placebo (NCT02282761)
- 2025-10-02Results posted on the registry: Intra-Cellular Therapies, Inc., ITI-007 + Risperidone (NCT02469155)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision